Opto Circuits subsidiary Eurocor GmbH launches "DIOR"

Opto Circuits India Ltd has announced that Eurocor GmbH the Company's wholly owned subsidiary has launched its revolutionary product - DIOR, a paclitaxel-eluting balloon dilation catheter used in PTCA (percutaneous transluminal coronary angioplasty) procedures.

Dior is a unique, problem solving and life saving catheter. The first of its kind. It can be effectively used for the successful treatment of coronary in-stent restenosis and treatment of small-diameter (less than 2.5mm) coronary artery lesions, which is approximately 4 per cent of the total requirements. EuroCor is the only Company in the world to have obtained CE (Conformité Européen) certification for its drug eluting balloon catheters.

Approximately 4 million stents are in place today; 70 per cent are drug eluting ones and 30 per cent are bare metal stents. The restenosis rates are 10 per cent and 30 per cent on drug eluting and bare metal stents, respectively. EuroCor expects a world market size of 8,56,000 balloon catheters which approximately translates to US$ 1.20 Billion. With the only CE accreditation in place, EuroCor is well poised for a massive market share in this product category.

Re-stenosis is usually treated with placing another Stent within the existing Stent, at times, resulting in even higher re-stenosis. By the application of Dior, the long-term patient outcome is significantly more favorable. Dior enables the Cardiologist to treat in-stent re-stenosis without placing another Stent into the Stent and thus rendering the patient safe for further interventions, if needed.

DIOR, as a concept, was conceived by EuroCor when the experts at the Company realized the incidence of in-stent restenosis after a PTCA intervention ranged highly from 5-35 per cent. In cases of re-stenting, it became apparent that the local administration of drugs would need to be prolonged in order to be beneficial. Under these circumstances, the most pronounced form was seen with paclitaxel balloon coated catheters.

Clinical evidence trials, too, concluded that the treatment with Paclitaxel eluting balloon dilation catheters significantly reduce the incidence of restenosis.

Source : Equity Bulls

Keywords